engineered an in situ DC vaccine, termed HELA‐Exos, by loading immunogenic cell death immunogenic cell death (ICD) inducers, human neutrophil elastase (ELANE) and Hiltonol (TLR3 agonist) into BC‐derived exosomes engineered with α‐lactalbumin (α‐LA). The gene discussed is TLR3; the disease is breast cancer.